2026-04-25T09:32:30Z
https://www.pub.unibl.org/oai
oai:pub.unibl.org:30875
2025-12-19T04:43:51Z
Sorafenib as first line treatment for advanced liver cancer - are expiries
https://www.unibl.org/sr-lat/fis/zaposlen/3371-zdenka-gojkovic
https://www.unibl.org/sr-lat/fis/zaposlen/3512-sasa-jungic
/unibl/author/Ivanka Rakita
/unibl/author/Živko Vranješ
/unibl/author/Radmila Rašeta
/unibl/author/G. Marić
/unibl/author/M. Vještica
/unibl/author/S. Mijatović
/unibl/author/P. Dašić
/unibl/author/M. Vižin
/unibl/author/Jelena Rožić
2012
Conference Paper
text
/unibl/sci/idNaucniRad:25647
Annals of Oncology
Annals of Oncology 2012; 23(4) iv57
Annals of Oncology 2012; 23(4) iv57
Z. Gojković, S. Jungić, I. Rakita, Ž. Vranješ, R. Rašeta, G. Marić, M. Vještica, S. Mijatović, P. Dašić, M. Vižin, J. Rožić, Sorafenib as first line treatment for advanced liver cancer - are expiries, Annals of Oncology 2012; 23(4) iv57, 2012